샘플 요청 목록

 카트 문의
시장보고서
상품코드
1872176

단일염기다형성(SNP) 지노타이핑 : 세계 시장 점유율과 순위, 총판매량 및 수요 예측(2025-2031년)

Single Nucleotide Polymorphism (SNP) Genotyping - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
발행일: | 리서치사: QYResearch | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

세계의 단일염기다형성(SNP) 지노타이핑 시장 규모는 2024년에 247억 1,000만 달러로 추정되며, 2025-2031년의 예측 기간에 CAGR 21.1%로 성장하며, 2031년까지 927억 5,000만 달러로 확대할 것으로 예측되고 있습니다.

단일염기다형성(SNP) 유전형질분석은 동일 종내 개체 간에 관찰되는 단일염기다형성(SNP)의 유전적 변이를 측정하는 방법입니다. 이는 보다 광범위한 유전적 변이를 측정하는 유전형질의 한 형태입니다. SNP 유전자형 분석은 가장 많이 존재하는 유전자 마커일 뿐만 아니라 가장 유망한 마커이기도 합니다. 분자 마커 개발에서 가장 큰 잠재력을 가지고 있으며, 대규모 및 첨단 자동화를 실현할 수 있으므로 방대한 수의 검출 및 분석에 적합합니다. 생물학, 농업, 의학, 생물 진화 등의 분야에서 널리 활용되고 있습니다.

세계 SNP 유전체 분석의 주요 기업으로는 Illumina, Affymetrix, Applied Biosystems, Agilent Technologies, Beckman Coulter 등을 들 수 있습니다. 상위 5개사의 점유율은 약 65%를 차지하고 있습니다. 북미가 가장 큰 시장으로 약 40%의 점유율을 차지하고 있으며, 유럽과 일본이 약 35%를 차지하고 있습니다. 제품별 부문에는 전위(Transversion)와 전이(Transition)가 포함됩니다. 용도별로는 진단용이 가장 큰 비중을 차지하고 있으며, 동물, 식물, 조사 등이 그 뒤를 잇고 있습니다.

이 보고서는 단일염기다형성(SNP) 유전자형 분석 세계 시장에 대해 총매출액, 주요 기업의 시장 점유율 및 순위를 중심으로 지역별, 국가별, 유형별, 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.

SNP 유전자형 분석 시장 규모, 추정치 및 예측은 2024년을 기준 연도로 하여 2020-2031년의 과거 데이터와 예측 데이터를 기반으로 한 판매 매출로 제공됩니다. 정량적, 정성적 분석을 통해 독자들이 비즈니스/성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 포지셔닝 분석, SNP 유전형 분석에 대한 정보에 기반한 비즈니스 의사결정을 내릴 수 있도록 도와드립니다.

시장 세분화

기업별

  • Illumina
  • Affymetrix
  • Applied Biosystems
  • Agilent Technologies
  • Beckman Coulter
  • Roche
  • Qiagen
  • Luminex Corporation
  • Enzo Life Sciences
  • Bio-rad
  • Sequenom
  • Ocimum Biosolutions
  • GE Healthcare
  • GenScript
  • Douglas Scientific
  • BGI
  • Beijing Sunbiotech
  • HuaGene Biotech
  • Generay Biotech
  • Benegene
  • Shanghai Biochip
  • GENESKY
  • HD Biosciences

유형별 부문

  • 트랜지션
  • 트랜스버전

용도별 부문

  • 진단
  • 동물
  • 식물
  • 연구
  • 기타

지역별

  • 북미
    • 미국
    • 캐나다
  • 아시아태평양
    • 중국
    • 일본
    • 한국
    • 동남아시아
    • 인도
    • 호주
    • 기타 아시아태평양
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 네덜란드
    • 북유럽 국가
    • 기타 유럽
  • 라틴아메리카
    • 멕시코
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • 튀르키예
    • 사우디아라비아
    • 아랍에미리트
    • 기타 중동 및 아프리카
KSA 25.12.23

자주 묻는 질문

  • 단일염기다형성(SNP) 지노타이핑 시장 규모는 어떻게 예측되나요?
  • 단일염기다형성(SNP) 유전자형 분석의 주요 활용 분야는 무엇인가요?
  • 세계 SNP 유전체 분석 시장의 주요 기업은 어디인가요?
  • SNP 유전자형 분석의 용도별 비중은 어떻게 되나요?
  • 북미 지역의 SNP 유전체 분석 시장 점유율은 얼마인가요?

The global market for Single Nucleotide Polymorphism (SNP) Genotyping was estimated to be worth US$ 24710 million in 2024 and is forecast to a readjusted size of US$ 92750 million by 2031 with a CAGR of 21.1% during the forecast period 2025-2031.

Single Nucleotide Polymorphism (SNP) Genotyping is the measurement of genetic variations of single nucleotide polymorphisms (SNPs) between members of a species. It is a form of genotyping, which is the measurement of more general genetic variation. SNP genotyping is not only the genetic markers present in most, but also the most promising markers. SNP genotyping as the most potential for development of molecular markers, it cans achieve large-scale highly automated, thus it is more suited to a huge number of detection and analysis, has been widely used in biology, agriculture, medicine, biological evolution and other fields.

Global Single Nucleotide Polymorphism (SNP) Genotyping key players include Illumina, Affymetrix, Applied Biosystems, Agilent Technologies, Beckman Coulter, etc. Global top five players hold a share about 65%. North America is the largest market, with a share about 40%, followed by Europe and Japan, having a total share about 35 percent. In terms of product, the segment includes Transversion, Transition. And in terms of application, the largest application is Diagnostics, followed by Animal, Plant, Research, etc.

This report aims to provide a comprehensive presentation of the global market for Single Nucleotide Polymorphism (SNP) Genotyping, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Single Nucleotide Polymorphism (SNP) Genotyping by region & country, by Type, and by Application.

The Single Nucleotide Polymorphism (SNP) Genotyping market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Single Nucleotide Polymorphism (SNP) Genotyping.

Market Segmentation

By Company

  • Illumina
  • Affymetrix
  • Applied Biosystems
  • Agilent Technologies
  • Beckman Coulter
  • Roche
  • Qiagen
  • Luminex Corporation
  • Enzo Life Sciences
  • Bio-rad
  • Sequenom
  • Ocimum Biosolutions
  • GE Healthcare
  • GenScript
  • Douglas Scientific
  • BGI
  • Beijing Sunbiotech
  • HuaGene Biotech
  • Generay Biotech
  • Benegene
  • Shanghai Biochip
  • GENESKY
  • HD Biosciences

Segment by Type

  • Transversion
  • Transition

Segment by Application

  • Diagnostics
  • Animal
  • Plant
  • Research
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Single Nucleotide Polymorphism (SNP) Genotyping company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Single Nucleotide Polymorphism (SNP) Genotyping in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Single Nucleotide Polymorphism (SNP) Genotyping in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Single Nucleotide Polymorphism (SNP) Genotyping Product Introduction
  • 1.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Market Size Forecast (2020-2031)
  • 1.3 Single Nucleotide Polymorphism (SNP) Genotyping Market Trends & Drivers
    • 1.3.1 Single Nucleotide Polymorphism (SNP) Genotyping Industry Trends
    • 1.3.2 Single Nucleotide Polymorphism (SNP) Genotyping Market Drivers & Opportunity
    • 1.3.3 Single Nucleotide Polymorphism (SNP) Genotyping Market Challenges
    • 1.3.4 Single Nucleotide Polymorphism (SNP) Genotyping Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Players Revenue Ranking (2024)
  • 2.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Revenue by Company (2020-2025)
  • 2.3 Key Companies Single Nucleotide Polymorphism (SNP) Genotyping Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Single Nucleotide Polymorphism (SNP) Genotyping Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Single Nucleotide Polymorphism (SNP) Genotyping
  • 2.6 Single Nucleotide Polymorphism (SNP) Genotyping Market Competitive Analysis
    • 2.6.1 Single Nucleotide Polymorphism (SNP) Genotyping Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Single Nucleotide Polymorphism (SNP) Genotyping Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Single Nucleotide Polymorphism (SNP) Genotyping as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Transversion
    • 3.1.2 Transition
  • 3.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type
    • 3.2.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, by Type (2020-2031)
    • 3.2.3 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Diagnostics
    • 4.1.2 Animal
    • 4.1.3 Plant
    • 4.1.4 Research
    • 4.1.5 Others
  • 4.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application
    • 4.2.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, by Application (2020-2031)
    • 4.2.3 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region
    • 5.1.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region (2020-2025)
    • 5.1.3 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region (2026-2031)
    • 5.1.4 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 5.2.2 North America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 5.3.2 Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 5.5.2 South America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 6.3.2 United States Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 6.4.2 Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 6.5.2 China Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 6.6.2 Japan Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 6.7.2 South Korea Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 6.9.2 India Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Illumina
    • 7.1.1 Illumina Profile
    • 7.1.2 Illumina Main Business
    • 7.1.3 Illumina Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.1.4 Illumina Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Illumina Recent Developments
  • 7.2 Affymetrix
    • 7.2.1 Affymetrix Profile
    • 7.2.2 Affymetrix Main Business
    • 7.2.3 Affymetrix Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.2.4 Affymetrix Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Affymetrix Recent Developments
  • 7.3 Applied Biosystems
    • 7.3.1 Applied Biosystems Profile
    • 7.3.2 Applied Biosystems Main Business
    • 7.3.3 Applied Biosystems Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.3.4 Applied Biosystems Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Applied Biosystems Recent Developments
  • 7.4 Agilent Technologies
    • 7.4.1 Agilent Technologies Profile
    • 7.4.2 Agilent Technologies Main Business
    • 7.4.3 Agilent Technologies Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.4.4 Agilent Technologies Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Agilent Technologies Recent Developments
  • 7.5 Beckman Coulter
    • 7.5.1 Beckman Coulter Profile
    • 7.5.2 Beckman Coulter Main Business
    • 7.5.3 Beckman Coulter Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.5.4 Beckman Coulter Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Beckman Coulter Recent Developments
  • 7.6 Roche
    • 7.6.1 Roche Profile
    • 7.6.2 Roche Main Business
    • 7.6.3 Roche Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.6.4 Roche Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Roche Recent Developments
  • 7.7 Qiagen
    • 7.7.1 Qiagen Profile
    • 7.7.2 Qiagen Main Business
    • 7.7.3 Qiagen Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.7.4 Qiagen Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Qiagen Recent Developments
  • 7.8 Luminex Corporation
    • 7.8.1 Luminex Corporation Profile
    • 7.8.2 Luminex Corporation Main Business
    • 7.8.3 Luminex Corporation Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.8.4 Luminex Corporation Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Luminex Corporation Recent Developments
  • 7.9 Enzo Life Sciences
    • 7.9.1 Enzo Life Sciences Profile
    • 7.9.2 Enzo Life Sciences Main Business
    • 7.9.3 Enzo Life Sciences Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.9.4 Enzo Life Sciences Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Enzo Life Sciences Recent Developments
  • 7.10 Bio-rad
    • 7.10.1 Bio-rad Profile
    • 7.10.2 Bio-rad Main Business
    • 7.10.3 Bio-rad Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.10.4 Bio-rad Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Bio-rad Recent Developments
  • 7.11 Sequenom
    • 7.11.1 Sequenom Profile
    • 7.11.2 Sequenom Main Business
    • 7.11.3 Sequenom Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.11.4 Sequenom Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Sequenom Recent Developments
  • 7.12 Ocimum Biosolutions
    • 7.12.1 Ocimum Biosolutions Profile
    • 7.12.2 Ocimum Biosolutions Main Business
    • 7.12.3 Ocimum Biosolutions Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.12.4 Ocimum Biosolutions Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Ocimum Biosolutions Recent Developments
  • 7.13 GE Healthcare
    • 7.13.1 GE Healthcare Profile
    • 7.13.2 GE Healthcare Main Business
    • 7.13.3 GE Healthcare Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.13.4 GE Healthcare Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.13.5 GE Healthcare Recent Developments
  • 7.14 GenScript
    • 7.14.1 GenScript Profile
    • 7.14.2 GenScript Main Business
    • 7.14.3 GenScript Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.14.4 GenScript Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.14.5 GenScript Recent Developments
  • 7.15 Douglas Scientific
    • 7.15.1 Douglas Scientific Profile
    • 7.15.2 Douglas Scientific Main Business
    • 7.15.3 Douglas Scientific Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.15.4 Douglas Scientific Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.15.5 Douglas Scientific Recent Developments
  • 7.16 BGI
    • 7.16.1 BGI Profile
    • 7.16.2 BGI Main Business
    • 7.16.3 BGI Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.16.4 BGI Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.16.5 BGI Recent Developments
  • 7.17 Beijing Sunbiotech
    • 7.17.1 Beijing Sunbiotech Profile
    • 7.17.2 Beijing Sunbiotech Main Business
    • 7.17.3 Beijing Sunbiotech Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.17.4 Beijing Sunbiotech Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.17.5 Beijing Sunbiotech Recent Developments
  • 7.18 HuaGene Biotech
    • 7.18.1 HuaGene Biotech Profile
    • 7.18.2 HuaGene Biotech Main Business
    • 7.18.3 HuaGene Biotech Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.18.4 HuaGene Biotech Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.18.5 HuaGene Biotech Recent Developments
  • 7.19 Generay Biotech
    • 7.19.1 Generay Biotech Profile
    • 7.19.2 Generay Biotech Main Business
    • 7.19.3 Generay Biotech Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.19.4 Generay Biotech Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.19.5 Generay Biotech Recent Developments
  • 7.20 Benegene
    • 7.20.1 Benegene Profile
    • 7.20.2 Benegene Main Business
    • 7.20.3 Benegene Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.20.4 Benegene Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.20.5 Benegene Recent Developments
  • 7.21 Shanghai Biochip
    • 7.21.1 Shanghai Biochip Profile
    • 7.21.2 Shanghai Biochip Main Business
    • 7.21.3 Shanghai Biochip Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.21.4 Shanghai Biochip Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.21.5 Shanghai Biochip Recent Developments
  • 7.22 GENESKY
    • 7.22.1 GENESKY Profile
    • 7.22.2 GENESKY Main Business
    • 7.22.3 GENESKY Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.22.4 GENESKY Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.22.5 GENESKY Recent Developments
  • 7.23 HD Biosciences
    • 7.23.1 HD Biosciences Profile
    • 7.23.2 HD Biosciences Main Business
    • 7.23.3 HD Biosciences Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.23.4 HD Biosciences Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.23.5 HD Biosciences Recent Developments

8 Industry Chain Analysis

  • 8.1 Single Nucleotide Polymorphism (SNP) Genotyping Industrial Chain
  • 8.2 Single Nucleotide Polymorphism (SNP) Genotyping Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Single Nucleotide Polymorphism (SNP) Genotyping Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Single Nucleotide Polymorphism (SNP) Genotyping Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제